131629Modulating intracellular oncology targets using Adhirons™ – a novel therapeutic approachClosedFeasibility StudiesInnovate UKTecrea and Leeds University BioScreening Technology group will collaborate to establish the feasibility of using peptide aptamers based on the Leeds's Andiron platform to modulate intracellular oncology targets. In particular KRas and Bcl-xL. The key innovations are the use of Tecrea's safe nanoparticle based delivery system combined with a stable peptide aptamer platform to provide a new modality for target modulation and future therapy.